BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 9142315)

  • 1. Autologous lymphokine-activated killer cell therapy of lymphoproliferative disorders arising in organ transplant recipients.
    Nalesnik MA; Rao AS; Zeevi A; Fung JJ; Pham S; Furukawa H; Gritsch A; Klein G; Starzl TE
    Transplant Proc; 1997 May; 29(3):1905-6. PubMed ID: 9142315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients.
    Nalesnik MA; Rao AS; Furukawa H; Pham S; Zeevi A; Fung JJ; Klein G; Gritsch HA; Elder E; Whiteside TL; Starzl TE
    Transplantation; 1997 May; 63(9):1200-5. PubMed ID: 9158009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective treatment of high-grade lymphoproliferative disorder after renal transplantation using autologous lymphocyte activated killer cell therapy.
    Li PK; Tsang K; Szeto CC; Wong TY; To KF; Leung CB; Lui SF; Yu S; Lai FM
    Am J Kidney Dis; 1998 Nov; 32(5):813-9. PubMed ID: 9820452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.
    Khanna R; Bell S; Sherritt M; Galbraith A; Burrows SR; Rafter L; Clarke B; Slaughter R; Falk MC; Douglass J; Williams T; Elliott SL; Moss DJ
    Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10391-6. PubMed ID: 10468618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
    Muti G; Cantoni S; Oreste P; Klersy C; Gini G; Rossi V; D'Avanzo G; Comoli P; Baldanti F; Montillo M; Nosari A; Morra E;
    Haematologica; 2002 Jan; 87(1):67-77. PubMed ID: 11801467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer risk following post-transplant lymphoproliferative disorders in solid organ transplant recipients.
    Mahale P; Engels EA; Lynch CF; Morton LM
    Br J Haematol; 2019 Jul; 186(2):347-351. PubMed ID: 30820931
    [No Abstract]   [Full Text] [Related]  

  • 7. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations.
    Walker RC; Paya CV; Marshall WF; Strickler JG; Wiesner RH; Velosa JA; Habermann TM; Daly RC; McGregor CG
    J Heart Lung Transplant; 1995; 14(2):214-21. PubMed ID: 7779838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnosis and treatment of posttransplant lymphoproliferative disorders.
    Nalesnik MA; Makowka L; Starzl TE
    Curr Probl Surg; 1988 Jun; 25(6):367-472. PubMed ID: 3063441
    [No Abstract]   [Full Text] [Related]  

  • 9. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center.
    Mihalov ML; Gattuso P; Abraham K; Holmes EW; Reddy V
    Clin Transplant; 1996 Jun; 10(3):248-55. PubMed ID: 8826661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication.
    Comoli P; Labirio M; Basso S; Baldanti F; Grossi P; Furione M; Viganò M; Fiocchi R; Rossi G; Ginevri F; Gridelli B; Moretta A; Montagna D; Locatelli F; Gerna G; Maccario R
    Blood; 2002 Apr; 99(7):2592-8. PubMed ID: 11895798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Post-transplantation lymphoproliferative disorder in childhood].
    Stréhn A; Szőnyi L; Kriván G; Kovács L; Reusz G; Szabó A; Rényi I; Kovács G; Dezsőfi A
    Orv Hetil; 2014 Feb; 155(8):313-8. PubMed ID: 24534879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of posttransplant lymphoproliferative disorders following solid organ transplant: an update.
    Dierickx D; Tousseyn T; De Wolf-Peeters C; Pirenne J; Verhoef G
    Leuk Lymphoma; 2011 Jun; 52(6):950-61. PubMed ID: 21338285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center.
    Leblond V; Sutton L; Dorent R; Davi F; Bitker MO; Gabarre J; Charlotte F; Ghoussoub JJ; Fourcade C; Fischer A
    J Clin Oncol; 1995 Apr; 13(4):961-8. PubMed ID: 7707124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy.
    Starzl TE; Nalesnik MA; Porter KA; Ho M; Iwatsuki S; Griffith BP; Rosenthal JT; Hakala TR; Shaw BW; Hardesty RL
    Lancet; 1984 Mar; 1(8377):583-7. PubMed ID: 6142304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR T Cell Therapy for Post-Transplant Lymphoproliferative Disorder After Solid Organ Transplantation: A Safe and Feasible Therapy for an Orphan Disease.
    Ibrahim U; Bassil C; Chavez JC; Khimani F; Jain MD; Locke FL; Osman K; Lazaryan A
    Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):772-778. PubMed ID: 37263876
    [No Abstract]   [Full Text] [Related]  

  • 16. Posttransplantation lymphoproliferative disorders in pediatric thoracic organ recipients.
    Boyle GJ; Michaels MG; Webber SA; Knisely AS; Kurland G; Cipriani LA; Griffith BP; Fricker FJ
    J Pediatr; 1997 Aug; 131(2):309-13. PubMed ID: 9290623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-transplantation lymphoproliferative disorders arising in solid organ transplant recipients are usually of recipient origin.
    Chadburn A; Suciu-Foca N; Cesarman E; Reed E; Michler RE; Knowles DM
    Am J Pathol; 1995 Dec; 147(6):1862-70. PubMed ID: 7495309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of autologous blood transfusion on natural killer and lymphokine-activated killer cell activities in cancer surgery.
    Heiss MM; Fasol-Merten K; Allgayer H; Ströhlein MA; Tarabichi A; Wallner S; Eissner HI; Jauch KW; Schildberg FW
    Vox Sang; 1997; 73(4):237-45. PubMed ID: 9407641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphoproliferative disease in organ transplant recipients.
    Nalesnik MA
    Springer Semin Immunopathol; 1991; 13(2):199-216. PubMed ID: 1664986
    [No Abstract]   [Full Text] [Related]  

  • 20. Malignancies in organ transplant recipients.
    Kauffman HM
    J Surg Oncol; 2006 Oct; 94(5):431-3. PubMed ID: 16967458
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.